Jefferies initiated coverage of TransMedics (TMDX) with a Buy rating and $145 price target The company has developed “differentiated” technology and a service/ transport model, enabling higher utilization and greater penetration for livers, hearts, and lungs, the analyst tells investors in a research note. The firm sees above-consensus growth for TransMedics in 2027, driven by its next-generation heart and lung trials.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- Buy Rating for TransMedics Group: Innovative Organ Care System and Promising Growth Prospects
- TransMedics added to ‘Tactical Underperform’ list at Evercore ISI
- TransMedics Group Acquires Aircraft for Organ Transport
- TransMedics Group: Strong Long-Term Investment Despite Short-Term Sales Fluctuations
- TransMedics, Mercedes-Benz partner on organ transportation across Italy